Brown Advisory Inc. grew its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,591,204 shares of the medical research company’s stock after buying an additional 187,219 shares […]
NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2023 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of -$0.28–$0.23 for the period, compared to the consensus estimate of -$0.36. The company issued revenue guidance of $565.00 million-$575.00 million, compared to the consensus revenue estimate of $562.42 million. NeoGenomics also updated […]
Dillon & Associates Inc. bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,000 shares of the medical research company’s stock, valued at approximately $272,000. Other hedge funds and other […]
Shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price […]
Yarbrough Capital LLC bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,572 shares of the medical research company’s stock, valued at approximately $376,000. Other large investors have also recently bought […]